Robert E. Abernathy - 05 Aug 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
Director
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Abernathy
Issuer symbol
HAE
Transactions as of
05 Aug 2022
Net transactions value
$0
Form type
4
Filing time
08 Aug 2022, 17:19:04 UTC
Previous filing
01 Jul 2022
Next filing
03 Oct 2022

Key filing fact

Robert E. Abernathy filed Form 4 for HAEMONETICS CORP (HAE) on 08 Aug 2022.

Key facts

  • This page summarizes Robert E. Abernathy's Form 4 filing for HAEMONETICS CORP (HAE).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 08 Aug 2022, 17:19.

Change

  • Previous filing in this sequence was filed on 01 Jul 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

HAE transaction

Common Stock

Award

Transaction value
Shares
+2,730
Change %
+18%
Price
Shares after
17,855
Date
05 Aug 2022
Ownership
Direct
Footnotes
F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .